BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garcia-retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation: Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-7. [DOI: 10.1053/jhep.2002.31773] [Cited by in Crossref: 410] [Cited by in F6Publishing: 353] [Article Influence: 22.8] [Reference Citation Analysis]
Number Citing Articles
1 Campos-Varela I, Esteban JI, Bes M, Caralt M, Allende H, Rodríguez-Frías F, Salcedo MT, Sauleda S, Charco R, Guardia J, Esteban R, Castells L. Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1. J Viral Hepat 2014;21:e118-28. [PMID: 24620835 DOI: 10.1111/jvh.12246] [Reference Citation Analysis]
2 Chang LY, Ali AR, Hassan SS, AbuBakar S. Quantitative estimation of Nipah virus replication kinetics in vitro. Virol J 2006;3:47. [PMID: 16784519 DOI: 10.1186/1743-422X-3-47] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
3 Lens S, Mariño Z, Forns X. Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. Dig Liver Dis 2014;46 Suppl 5:S197-205. [PMID: 25458782 DOI: 10.1016/j.dld.2014.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
4 Botero RC. Should patients with chronic hepatitis C infection be transplanted? Transplant Proc. 2004;36:1449-1454. [PMID: 15251356 DOI: 10.1016/j.transproceed.2004.06.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
5 Nagai S, Yoshida A, Kohno K, Altshuler D, Nakamura M, Brown KA, Abouljoud MS, Moonka D. Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation. Hepatology. 2014;59:35-45. [PMID: 23728831 DOI: 10.1002/hep.26536] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
6 Pawlotsky JM, Chevaliez S. Preventing hepatitis C virus recurrence in liver transplant recipients: a role for adoptive immunotherapy? Hepatology. 2010;51:1072-1076. [PMID: 20198701 DOI: 10.1002/hep.23579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Gessoni G, Barin P, Valverde S, Giacomini A, Di Natale C, Orlandini E, Arreghini N, De Fusco G, Frigato A, Fezzi M, Antico F, Marchiori G. Biological qualification of blood units: considerations about the effects of sample's handling and storage on stability of nucleic acids. Transfus Apher Sci 2004;30:197-203. [PMID: 15172624 DOI: 10.1016/j.transci.2003.11.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
8 Dragun J, Pérez-Del-Pulgar S, Crespo G, Ramírez S, Coto-Llerena M, Mensa L, García-Valdecasas JC, Navasa M, Forns X. Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting. Am J Transplant 2011;11:767-74. [PMID: 21401864 DOI: 10.1111/j.1600-6143.2011.03440.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
9 Tamura S, Sugawara Y, Yamashiki N, Kaneko J, Kokudo N, Makuuchi M. Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transpl Int. 2010;23:580-588. [PMID: 20028490 DOI: 10.1111/j.1432-2277.2009.01023.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
10 Akamatsu N, Sugawara Y. Liver transplantation and hepatitis C. Int J Hepatol 2012;2012:686135. [PMID: 22900194 DOI: 10.1155/2012/686135] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
11 Bárcena R, Moreno A, Rodríguez-Gandía MA, Albillos A, Arocena C, Blesa C, García-Hoz F, Graus J, Nuño J, López-Hervás P, Gajate L, Martínez A, Bermejo T, Mateos ML, Del Campo S; Hospital Ramón y Cajal Liver Transplant Group. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J Hepatol 2013;58:421-6. [PMID: 23073223 DOI: 10.1016/j.jhep.2012.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
12 Fox AN, Brown RS. Is the Patient a Candidate for Liver Transplantation? Clinics in Liver Disease 2012;16:435-48. [DOI: 10.1016/j.cld.2012.03.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
13 Suda G, Sakamoto N. Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. J Gastroenterol Hepatol 2021;36:1152-8. [PMID: 32667068 DOI: 10.1111/jgh.15189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351-1358. [PMID: 12774014 DOI: 10.1053/jhep.2003.50218] [Cited by in Crossref: 181] [Cited by in F6Publishing: 169] [Article Influence: 10.1] [Reference Citation Analysis]
15 Firpi RJ, Nelson DR. Pathogenesis of recurrent hepatitis C after liver transplantation. Curr hepatitis rep 2005;4:138-44. [DOI: 10.1007/s11901-005-0029-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26:531-548. [PMID: 23199510 DOI: 10.1016/j.bpg.2012.09.010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
17 Martini S, Tandoi F, Terzi di Bergamo L, Strona S, Lavezzo B, Sacco M, Maione F, Gonella F, Strignano P, Dell Olio D, Salizzoni M, Saracco GM, Romagnoli R. Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C-positive recipients. Liver Transpl 2017;23:915-24. [PMID: 28422425 DOI: 10.1002/lt.24772] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
18 El Awady MK, Bader El Din NG, Abdel Aziz Riad M, Omran MH, Abdelhafez TH, Elbaz TM, Hunter SS, Dawood RM, Abdel Aziz AO. Predictors of disease recurrence post living donor liver transplantation in end stage chronic HCV patients. Dis Markers 2014;2014:202548. [PMID: 24695489 DOI: 10.1155/2014/202548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, Yersiz H, Zimmerman MA, Durazo F, Han SH, Saab S, Gornbein J, Busuttil RW. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006;244:563-71. [PMID: 16998365 DOI: 10.1097/01.sla.0000237648.90600.e9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
20 Nebbia G, Mattes FM, Cholongitas E, Garcia-Diaz A, Samonakis DN, Burroughs AK, Emery VC. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl. 2007;13:130-135. [PMID: 17192909 DOI: 10.1002/lt.21037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
21 Fedoravicius A, Charlton M. Abnormal liver tests after liver transplantation. Clin Liver Dis (Hoboken) 2016;7:73-9. [PMID: 31041034 DOI: 10.1002/cld.540] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
22 Moreira RK, Salomao M, Verna EC, Brown RS, Lefkowitch JH. The Hepatitis Aggressiveness Score (HAS): A Novel Classification System for Post–Liver Transplantation Recurrent Hepatitis C. American Journal of Surgical Pathology 2013;37:104-13. [DOI: 10.1097/pas.0b013e31826a92ac] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
23 Berenguer M. Hepatitis C virus in liver transplantation: impact and treatment of hepatitis C virus recurrence: . Current Opinion in Organ Transplantation 2006;11:599-607. [DOI: 10.1097/mot.0b013e3280106c3d] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Cano A, Mariño Z, Millet O, Martínez-Arranz I, Navasa M, Falcón-Pérez JM, Pérez-Cormenzana M, Caballería J, Embade N, Forns X, Bosch J, Castro A, Mato JM. A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. Sci Rep 2017;7:10497. [PMID: 28874799 DOI: 10.1038/s41598-017-10807-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
25 Mensa L, Pérez-del-Pulgar S, Crespo G, Koutsoudakis G, Fernández-Carrillo C, Coto-Llerena M, Miquel R, Allende H, Castells L, Navasa M. Imaging of hepatitis C virus infection in liver grafts after liver transplantation. J Hepatol. 2013;59:271-278. [PMID: 23548198 DOI: 10.1016/j.jhep.2013.03.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
26 Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology. 2006;43:S207-S220. [PMID: 16447262 DOI: 10.1002/hep.21064] [Cited by in Crossref: 124] [Cited by in F6Publishing: 121] [Article Influence: 8.3] [Reference Citation Analysis]
27 Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, Fuertes A, Abradelo M, Lumbreras C, Moreno E, Solís-Herruzo JA. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006;12:1805-12. [PMID: 17133585 DOI: 10.1002/lt.20883] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 5.9] [Reference Citation Analysis]
28 Monrroy H, López-Lastra M, Soza A. Hepatitis C virus may have an entero-hepatic cycle which could be blocked with ezetimibe. Med Hypotheses 2017;102:51-5. [PMID: 28478831 DOI: 10.1016/j.mehy.2017.03.016] [Reference Citation Analysis]
29 Biggins SW, Terrault NA. Treatment of recurrent hepatitis C after liver transplantation. Clin Liver Dis. 2005;9:505-523, ix. [PMID: 16023980 DOI: 10.1016/j.cld.2005.05.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
30 Jüttner B, Younes A, Weissig A, Ahrens J, Becker T, Scheinichen D. Reduced post-operative neutrophil activation in liver transplant recipients suffering from post-hepatitic cirrhosis. Clin Transplant. 2009;23:921-929. [PMID: 19563486 DOI: 10.1111/j.1399-0012.2009.01016.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
31 Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, Markmann JF, Hertl M, Pomposelli JJ, Pomfret EA. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant. 2013;13:1047-1054. [PMID: 23356386 DOI: 10.1111/ajt.12083] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
32 Wadhawan M, Vij V, Makki K, Bansal N, Kumar A. Early Acute Severe HCV Recurrence After Transplantation: From Universal Mortality to Cure. J Clin Exp Hepatol 2017;7:28-32. [PMID: 28348468 DOI: 10.1016/j.jceh.2016.10.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Weston SJ, Leistikow RL, Reddy KR, Torres M, Wertheimer AM, Lewinsohn DM, Chou S, Davey MP, Corless C, O’Farrelly C. Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation. Hepatology. 2005;41:72-81. [PMID: 15619226 DOI: 10.1002/hep.20507] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
34 Brown RS. Hepatitis C and liver transplantation. Nature. 2005;436:973-978. [PMID: 16107838 DOI: 10.1038/nature04083] [Cited by in Crossref: 261] [Cited by in F6Publishing: 234] [Article Influence: 16.3] [Reference Citation Analysis]
35 Brown R, Emond JC. Managing Access to Liver Transplantation: Implications for Gastroenterology Practice. Gastroenterology 2007;132:1152-63. [DOI: 10.1053/j.gastro.2007.01.054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
37 Llado L, Castellote J, Figueras J. Is retransplantation an option for recurrent hepatitis C cirrhosis after liver transplantation? J Hepatol. 2005;42:468-472. [PMID: 15763328 DOI: 10.1016/j.jhep.2005.01.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
38 Forns X, Berenguer M, Herzer K, Sterneck M, Donato MF, Andreone P, Fagiuoli S, Cieciura T, Durlik M, Calleja JL, Mariño Z, Shukla U, Verbinnen T, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, Janssen K, Kalmeijer R, Jessner W. Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. Transpl Infect Dis 2017;19. [PMID: 28295849 DOI: 10.1111/tid.12696] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
39 Coto-llerena M, Pérez-del-pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-tapias JM, Martorell J, Navasa M, Forns X. Donor and Recipient IL28B Polymorphisms in HCV-Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation: IL28B in HCV-Infected Liver Transplant Recipients. American Journal of Transplantation 2011;11:1051-7. [DOI: 10.1111/j.1600-6143.2011.03491.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
40 Mederacke I, Filmann N, Yurdaydin C, Bremer B, Puls F, Zacher BJ, Heidrich B, Tillmann HL, Rosenau J, Bock CT. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol. 2012;56:115-122. [PMID: 21762665 DOI: 10.1016/j.jhep.2011.06.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
41 Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, Wappler I, Manns MP, Wedemeyer H, Pietschmann T. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010;138:1875-1884. [PMID: 20152835 DOI: 10.1053/j.gastro.2010.02.004] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 5.3] [Reference Citation Analysis]
42 Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018;68:1298-1307. [PMID: 29672891 DOI: 10.1002/hep.30046] [Cited by in Crossref: 105] [Cited by in F6Publishing: 87] [Article Influence: 35.0] [Reference Citation Analysis]
43 Dhanasekaran R, Firpi RJ. Challenges of recurrent hepatitis C in the liver transplant patient. World J Gastroenterol 2014; 20(13): 3391-3400 [PMID: 24707122 DOI: 10.3748/wjg.v20.i13.3391] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
44 Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, Feinstone SM, Neumann AU. Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production. Gastroenterology 2005;128:1056-66. [DOI: 10.1053/j.gastro.2005.01.049] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 5.1] [Reference Citation Analysis]
45 Micheloud D, Salcedo M, Bañares R, Rincón D, Jensen J, Rodríguez J, Fernández-cruz E, Carbone Campoverde J, Resino S. High rate of infection and immune disorders in patients with hepatitis C virus after liver transplantation. Transplant Infectious Disease 2009;11:367-72. [DOI: 10.1111/j.1399-3062.2009.00408.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Carrión JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006;12:1791-8. [DOI: 10.1002/lt.20857] [Cited by in Crossref: 300] [Cited by in F6Publishing: 271] [Article Influence: 20.0] [Reference Citation Analysis]
47 Berenguer M, Charco R, Manuel Pascasio J, Ignacio Herrero J. Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. Liver Int. 2012;32:712-731. [PMID: 22221843 DOI: 10.1111/j.1478-3231.2011.02731.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
48 Burra P, De Martin E, Zanetto A, Senzolo M, Russo FP, Zanus G, Fagiuoli S. Hepatitis C virus and liver transplantation: where do we stand? Transpl Int 2016;29:135-52. [DOI: 10.1111/tri.12642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
49 Herzer K, Gerken G. Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World J Hepatol 2015; 7(3): 532-538 [PMID: 25848476 DOI: 10.4254/wjh.v7.i3.532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
50 Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis. 2004;17:363-371. [PMID: 15241083 DOI: 10.1097/01.qco.0000136934.06039.01] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
51 Rosen HR, Hinrichs DJ, Leistikow RL, Callender G, Wertheimer AM, Nishimura MI, Lewinsohn DM. Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation. J Immunol 2004;173:5355-9. [PMID: 15494481 DOI: 10.4049/jimmunol.173.9.5355] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
52 Castedal M, Felldin M, Bäckman L, Olausson M, Friman S. Preemptive Therapy With Pegylated Interferon Alpha-2b and Ribavirin After Liver Transplantation for Hepatitis C Cirrhosis. Transplantation Proceedings 2005;37:3313-4. [DOI: 10.1016/j.transproceed.2005.09.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
53 Nair SP, Marella HK, Maliakkal B, Snyder H, Handley C, Kothadia JP, Ali B, Satapathy SK, Molnar MZ, Clark I, Jain R, Helmick R, Eymard C, Eason JD. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome. Clin Transplant 2021;35:e14281. [PMID: 33690929 DOI: 10.1111/ctr.14281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. Transplant Int 2004;17:759-66. [DOI: 10.1111/j.1432-2277.2004.tb00508.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
55 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 600] [Cited by in F6Publishing: 563] [Article Influence: 75.0] [Reference Citation Analysis]
56 Marubashi S, Dono K, Miyamoto A, Takeda Y, Nagano H, Umeshita K, Monden M. Liver transplantation for hepatitis C. J Hepatobiliary Pancreat Surg 2006;13:382-92. [DOI: 10.1007/s00534-005-1078-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
57 Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013;33:56-62. [DOI: 10.1111/liv.12062] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
58 Gane E. Treatment of recurrent hepatitis C. Liver Transpl. 2002;8:S28-S37. [PMID: 12362295 DOI: 10.1053/jlts.2002.35860] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
59 Carrión JA, Forns X. Living donor liver transplantation and hepatitis C: lessons from the learning curve? Liver Transpl. 2007;13:18-20. [PMID: 17192905 DOI: 10.1002/lt.20914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Akamatsu N, Sugawara Y. Living-donor liver transplantation and hepatitis C. HPB Surg 2013;2013:985972. [PMID: 23401640 DOI: 10.1155/2013/985972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
61 Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int. 2005;18:1336-1345. [PMID: 16297052 DOI: 10.1111/j.1432-2277.2005.00217.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
62 Subramanian V, Seetharam AB, Vachharajani N, Tiriveedhi V, Angaswamy N, Ramachandran S, Crippin JS, Shenoy S, Chapman WC, Mohanakumar T, Anderson CD. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation 2011;92:1259-68. [PMID: 22011763 DOI: 10.1097/TP.0b013e318235a1ab] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
63 Cheung A, Levitsky J. Follow-up of the Post-Liver Transplantation Patient: A Primer for the Practicing Gastroenterologist. Clin Liver Dis. 2017;21:793-813. [PMID: 28987263 DOI: 10.1016/j.cld.2017.06.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Hughes MG, Chong TW, Smith RL, Evans HL, Iezzoni JC, Sawyer RG, Rudy CK, Pruett TL. HCV infection of the transplanted liver: changing CD81 and HVR1 variants immediately after liver transplantation. Am J Transplant. 2005;5:2504-2513. [PMID: 16162201 DOI: 10.1111/j.1600-6143.2005.01060.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
65 Tanaka Y, Ohira M, Tashiro H, Imamura M, Chayama K, Ohdan H. Impact of alloimmune T cell responses on hepatitis C virus replication in liver transplant recipients. Hum Immunol 2014;75:1259-67. [PMID: 25300999 DOI: 10.1016/j.humimm.2014.09.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
66 Vasuri F, Malvi D, Gruppioni E, Grigioni WF, D’Errico-Grigioni A. Histopathological evaluation of recurrent hepatitis C after liver transplantation: A review. World J Gastroenterol 2014; 20(11): 2810-2824 [PMID: 24659874 DOI: 10.3748/wjg.v20.i11.2810] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
67 Samuel D. Antiviral treatment of recurrent hepatitis C after liver transplantation: The need for a multifaceted approach. Hepatology 2005;41:436-8. [DOI: 10.1002/hep.20623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
68 Stiffler JD, Nguyen M, Sohn JA, Liu C, Kaplan D, Seeger C. Focal distribution of hepatitis C virus RNA in infected livers. PLoS One 2009;4:e6661. [PMID: 19688046 DOI: 10.1371/journal.pone.0006661] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
69 Masuzaki R, Yamashiki N, Sugawara Y, Yoshida H, Tateishi R, Tamura S, Kaneko J, Hasegawa K, Kokudo N, Makuuchi M, Omata M. Assessment of liver stiffness in patients after living donor liver transplantation by transient elastography. Scand J Gastroenterol 2009;44:1115-20. [PMID: 19562623 DOI: 10.1080/00365520903078810] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
70 Walters KA, Katze MG. Using high-throughput genomics to study hepatitis C: what determines the outcome of infection? Antiviral Res 2009;81:198-208. [PMID: 19135090 DOI: 10.1016/j.antiviral.2008.12.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
71 Crespo G, Mariño Z, Navasa M, Forns X. Viral Hepatitis in Liver Transplantation. Gastroenterology 2012;142:1373-1383.e1. [DOI: 10.1053/j.gastro.2012.02.011] [Cited by in Crossref: 149] [Cited by in F6Publishing: 128] [Article Influence: 16.6] [Reference Citation Analysis]
72 Roche B, Samuel D. Hepatitis C virus: Up to the minute. Liver Transpl 2010;16:S26-35. [DOI: 10.1002/lt.22154] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
73 Powers KA, Ribeiro RM, Patel K, Pianko S, Nyberg L, Pockros P, Conrad AJ, McHutchison J, Perelson AS. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl. 2006;12:207-216. [PMID: 16447184 DOI: 10.1002/lt.20572] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
74 Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity”. Am J Transplant. 2014;14:994-1002. [PMID: 24730431 DOI: 10.1111/ajt.12714] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 9.9] [Reference Citation Analysis]
75 Toniutto P, Fabris C, Pirisi M. Antiviral treatment of hepatitis C. Expert Opin Pharmacother 2006;7:2025-35. [PMID: 17020430 DOI: 10.1517/14656566.7.15.2025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
76 Forns X. HCV: Alive and kicking in living donor liver grafts? Hepatology 2005;42:1258-60. [DOI: 10.1002/hep.20981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 McCaughan GW, Shackel NA, Bertolino P, Bowen DG. Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes. Transplantation. 2009;87:1105-1111. [PMID: 19384153 DOI: 10.1097/tp.0b013e31819dfa83] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
78 Herrmann E, Zeuzem S. Hepatitis C viral kinetic models. Cell Death Differ 2003;10:S7-8. [DOI: 10.1038/sj.cdd.4401118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
79 McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22:615-633. [PMID: 17444847 DOI: 10.1111/j.1440-1746.2007.04883.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 7.9] [Reference Citation Analysis]
80 Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60:78-86. [PMID: 23994384 DOI: 10.1016/j.jhep.2013.08.018] [Cited by in Crossref: 157] [Cited by in F6Publishing: 132] [Article Influence: 19.6] [Reference Citation Analysis]
81 Rodriguez-luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005;11:479-89. [DOI: 10.1002/lt.20424] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
82 Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, Eckhoff DE, Netto GJ, Katz E. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl. 2007;13:1521-1531. [PMID: 17969201 DOI: 10.1002/lt.21182] [Cited by in Crossref: 107] [Cited by in F6Publishing: 86] [Article Influence: 8.2] [Reference Citation Analysis]
83 Goldaracena N, Spetzler VN, Echeverri J, Kaths JM, Cherepanov V, Persson R, Hodges MR, Janssen HL, Selzner N, Grant DR, Feld JJ, Selzner M. Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion. Am J Transplant. 2017;17:970-978. [PMID: 27805315 DOI: 10.1111/ajt.14100] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
84 Burra P, Belli LS, Ginanni Corradini S, Volpes R, Marzioni M, Giannini E, Toniutto P. Common issues in the management of patients in the waiting list and after liver transplantation. Dig Liver Dis 2017;49:241-53. [PMID: 28096056 DOI: 10.1016/j.dld.2016.12.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
85 Abaalkhail F, Elsiesy H, Elbeshbeshy H, Shawkat M, Yousif S, Ullah W, Alabbad S, Al-Jedai A, Ajlan A, Broering D, Saab S, Al Sebayel M, Al-Hamoudi W. Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting. Transplantation 2017;101:2739-45. [PMID: 28795982 DOI: 10.1097/TP.0000000000001907] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Berenguer M. Treatment of hepatitis C after liver transplantation. Clin Liver Dis 2005;9:579-600, vi. [PMID: 16207565 DOI: 10.1016/j.cld.2005.08.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
87 Hughes MG, Rudy CK, Chong TW, Smith RL, Evans HL, Iezzoni JC, Sawyer RG, Pruett TL. E2 quasispecies specificity of hepatitis C virus association with allografts immediately after liver transplantation: Allograft Selectivity for HVR1 Quasispecies. Liver Transpl 2004;10:208-16. [DOI: 10.1002/lt.20060] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
88 Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt-Sarif T, Chang P, Kivett V, Castells L. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485-1494. [PMID: 25557906 DOI: 10.1002/hep.27681] [Cited by in Crossref: 181] [Cited by in F6Publishing: 161] [Article Influence: 30.2] [Reference Citation Analysis]
89 López-Labrador FX, Berenguer M, Sempere A, Prieto M, Sirera R, González-Molina A, Ortiz V, Marty ML, Berenguer J, Gobernado M. Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2004;10:217-227. [PMID: 14762859 DOI: 10.1002/lt.20066] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
90 Tang L, Ward H, Kattakuzhy S, Wilson E, Kottilil S. Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. Expert Rev Gastroenterol Hepatol 2016;10:21-36. [PMID: 26558305 DOI: 10.1586/17474124.2016.1119042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
91 Arjal RR, Burton Jr JR, Villamil F, Rosen HR. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Alimentary Pharmacology & Therapeutics 2007;26:127-40. [DOI: 10.1111/j.1365-2036.2007.03364.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
92 Garcia-retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, Bruguera M, Fuster J, Garcia-valdecasas JC, Rimola A. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004;40:699-707. [DOI: 10.1002/hep.20357] [Cited by in Crossref: 157] [Cited by in F6Publishing: 128] [Article Influence: 9.2] [Reference Citation Analysis]
93 Akamatsu N, Sugawara Y, Kokudo N, Eguchi S, Fujiwara T, Ohdan H, Nagano H, Taketomi A, Kitagawa Y, Shimada M. Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int. 2014;27:767-774. [PMID: 24684710 DOI: 10.1111/tri.12329] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
94 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264. [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023] [Cited by in Crossref: 847] [Cited by in F6Publishing: 801] [Article Influence: 84.7] [Reference Citation Analysis]
95 McCaughan GW, Zekry A. Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. Liver Transpl. 2003;9:S21-S27. [PMID: 14586891 DOI: 10.1053/jlts.2003.50269] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
96 Tamura S, Sugawara Y. Treatment strategy for hepatitis C after liver transplantation. J Hepatobiliary Pancreat Surg 2008;15:111-23. [DOI: 10.1007/s00534-007-1295-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
97 de la Peña-moral JM, Pons JA, Tome S, Gude F, Miras M, Bermejo J, Ramirez P, Berenguer M, Varo E, Forteza J, Parrilla P. Acute cellular rejection versus recurrent hepatitis C after liver transplantation: Clinical and pathological features driving a rational diagnostic approach: Acute rejection vs recurrent HCV after LT. Hepatol Res 2015;45:423-31. [DOI: 10.1111/hepr.12369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
98 Moreira RK. Recurrent hepatitis C and acute allograft rejection: clinicopathologic features with emphasis on the differential diagnosis between these entities. Adv Anat Pathol. 2011;18:393-405. [PMID: 21841407 DOI: 10.1097/pap.0b013e31822a5a10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Tawar RG, Heydmann L, Bach C, Schüttrumpf J, Chavan S, King BJ, McClure CP, Ball JK, Pessaux P, Habersetzer F, Bartenschlager R, Zeisel MB, Baumert TF. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin. Hepatology 2016;64:1495-506. [PMID: 27531416 DOI: 10.1002/hep.28767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
100 Zhuang X, Lai AG, McKeating JA, Rowe I, Balfe P. Daytime variation in hepatitis C virus replication kinetics following liver transplant. Wellcome Open Res 2018;3:96. [PMID: 30175249 DOI: 10.12688/wellcomeopenres.14696.2] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
101 Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res 2020;50:791-816. [PMID: 32343477 DOI: 10.1111/hepr.13503] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
102 Hilgard P, Kahraman A, Lehmann N, Seltmann C, Beckebaum S, Ross RS, Baba HA, Malago M, Broelsch CE, Gerken G. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: Effects on virus replication and recurrent hepatitis. World J Gastroenterol 2006; 12(5): 697-702 [PMID: 16521181 DOI: 10.3748/wjg.v12.i5.697] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
103 Massaguer A, Forns X, Costa J, Feliu A, García-Retortillo M, Navasa M, Rimola A, García-Valdecasas JC, Sánchez-Tapias JM. Performance of hepatitis C virus core antigen immunoassay in monitoring viral load after liver transplantation. Transplantation 2005;79:1441-4. [PMID: 15912117 DOI: 10.1097/01.tp.0000158356.81437.fa] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
104 Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008;14 Suppl 2:S58-S66. [PMID: 18825697 DOI: 10.1002/lt.21624] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
105 Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl. 2003;9:S95-S100. [PMID: 14586903 DOI: 10.1053/jlts.2003.50255] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
106 Maina A, Ciccorossi P, Oliveri F, Filipponi F, Brunetto M. Diagnosis and monitoring of hepatitis virus infection in liver transplant patients. Transplantation Proceedings 2003;35:1025-7. [DOI: 10.1016/s0041-1345(03)00303-8] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
107 Gane E. Liver Transplantation for Chronic Hepatitis B and C. In: Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ, editors. Viral Hepatitis. Oxford: John Wiley & Sons, Ltd; 2013. pp. 203-17. [DOI: 10.1002/9781118637272.ch15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Vukotic R, Conti F, Fagiuoli S, Morelli MC, Pasulo L, Colpani M, Foschi FG, Berardi S, Pianta P, Mangano M. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. J Viral Hepat. 2017;24:858-864. [PMID: 28370880 DOI: 10.1111/jvh.12712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
109 Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12:1192-1204. [PMID: 16868944 DOI: 10.1002/lt.20865] [Cited by in Crossref: 100] [Cited by in F6Publishing: 82] [Article Influence: 7.1] [Reference Citation Analysis]
110 Méndez-sánchez N, Paraná R, Cheinquer H, Alves de Mattos A, Gadano A, Silva M, Pessôa MG, Gomes-ferraz ML, Soza A, Mendes-correa MC, Chávez-tapia NC, Dagher L, Padilla M, Hernandez N, Sánchez-avila JF, Contreras F, Moraes-coelho HS, Parise ER, Bessone F, Uribe M. Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. Annals of Hepatology 2014;13:S4-S66. [DOI: 10.1016/s1665-2681(19)30920-2] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
111 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
112 Kwo PY, Saxena R, Cummings OW, Tector AJ. Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus. Liver Transpl 2007;13:1710-3. [DOI: 10.1002/lt.21295] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
113 Bohne F, Londoño MC, Benítez C, Miquel R, Martínez-Llordella M, Russo C, Ortiz C, Bonaccorsi-Riani E, Brander C, Bauer T, Protzer U, Jaeckel E, Taubert R, Forns X, Navasa M, Berenguer M, Rimola A, Lozano JJ, Sánchez-Fueyo A. HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. Sci Transl Med 2014;6:242ra81. [PMID: 24964989 DOI: 10.1126/scitranslmed.3008793] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 9.5] [Reference Citation Analysis]
114 Gerlei Z, Sárváry E, Lengyel G, Görög D, Fehérvári I, Nemes B, Kóbori L, Langer R. Measurement and Clinical Significance of Interleukin 28B in Hepatitis C Virus–Infected Liver Transplant Patients. Transplantation Proceedings 2012;44:2154-6. [DOI: 10.1016/j.transproceed.2012.07.101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
115 Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol. 2010;52:951-952. [PMID: 20413176 DOI: 10.1016/j.jhep.2010.02.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
116 Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Moreno Gonzales E, Charco R, Zieniewicz K, De Carlis L, Duvoux C;  all the contributing centers (www. eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018;69:810-817. [PMID: 29940268 DOI: 10.1016/j.jhep.2018.06.010] [Cited by in Crossref: 112] [Cited by in F6Publishing: 97] [Article Influence: 37.3] [Reference Citation Analysis]
117 Dahari H, Forns X, Neumann AU, Perelson AS. The extrahepatic contribution to HCV plasma viremia. Journal of Hepatology 2006;45:626-7. [DOI: 10.1016/j.jhep.2006.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
118 Schepis F, Vukotic R, Berzigotti A, Carrión JA, Forns X, Abraldes JG, García-valdecasas J, Navasa M, García-pagán J, Bosch J. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study: Response to Propranolol in Liver Transplantation. Liver Transpl 2013;19:450-6. [DOI: 10.1002/lt.23614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
119 Rosen HR. Hepatitis C virus in the human liver transplantation model. Clin Liver Dis. 2003;7:107-125. [PMID: 12691461 DOI: 10.1016/s1089-3261(02)00073-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
120 Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007;20:583-590. [PMID: 17433090 DOI: 10.1111/j.1432-2277.2007.00481.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
121 Galun E, Terrault NA, Eren R, Zauberman A, Nussbaum O, Terkieltaub D, Zohar M, Buchnik R, Ackerman Z, Safadi R, Ashur Y, Misrachi S, Liberman Y, Rivkin L, Dagan S. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol 2007;46:37-44. [PMID: 17112624 DOI: 10.1016/j.jhep.2006.08.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
122 Martinelli Ade L, Teixeira AC, Souza FF, Sankarankutty AK, Silva Ode C. Hepatitis C: a challenge to hepatologists and to the liver transplantation team. Acta Cir Bras 2006;21 Suppl 1:15-8. [PMID: 17013506 DOI: 10.1590/s0102-86502006000700004] [Reference Citation Analysis]
123 Morimoto H, Ishiyama K, Ishifuro M, Ohira M, Ide K, Tanaka Y, Tahara H, Teraoka Y, Yamashita M, Abe T, Hashimoto S, Hirata F, Tanimine N, Saeki Y, Shimizu S, Sakai H, Yano T, Tashiro H, Ohdan H. Clinical efficacy of simultaneous splenectomy in liver transplant recipients with hepatitis C virus. Transplant Proc 2014;46:770-3. [PMID: 24767345 DOI: 10.1016/j.transproceed.2013.12.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
124 O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology. 2008;134:1764-1776. [PMID: 18471553 DOI: 10.1053/j.gastro.2008.02.028] [Cited by in Crossref: 120] [Cited by in F6Publishing: 87] [Article Influence: 9.2] [Reference Citation Analysis]
125 Anand AC. Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation? J Clin Exp Hepatol. 2017;7:42-54. [PMID: 28348470 DOI: 10.1016/j.jceh.2017.01.116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
126 Baiocchi L, Angelico M, Petrolati A, Perrone L, Palmieri G, Battista S, Carbone M, Tariciotti L, Longhi C, Orlando G. Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. Am J Transplant. 2008;8:673-678. [PMID: 18294164 DOI: 10.1111/j.1600-6143.2007.02107.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
127 Lagging M, Duberg AS, Wejstål R, Weiland O, Lindh M, Aleman S, Josephson F; Swedish Consensus Group. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scand J Infect Dis 2012;44:502-21. [PMID: 22506634 DOI: 10.3109/00365548.2012.669045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
128 Liu LU, Schiano TD. Hepatitis C immune globulin (human) for the prevention of viral recurrence after liver transplantation. Expert Rev Clin Immunol 2007;3:125-30. [PMID: 20477101 DOI: 10.1586/1744666X.3.2.125] [Reference Citation Analysis]
129 Grassi A, Ballardini G. Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problem. World J Gastroenterol 2014; 20(32): 11095-11115 [PMID: 25170198 DOI: 10.3748/wjg.v20.i32.11095] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
130 Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opinion on Pharmacotherapy 2009;10:1929-38. [DOI: 10.1517/14656560903066811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
131 Harada N, Tamura S, Sugawara Y, Togashi J, Ishizawa T, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Tanaka T, Yamashiki N, Kokudo N. Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C. PLoS One 2014;9:e90462. [PMID: 24599320 DOI: 10.1371/journal.pone.0090462] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
132 Shi Y, Dong K, Zhang YG, Michel RP, Marcus V, Wang YY, Chen Y, Gao ZH. Sinusoidal endotheliitis as a histological parameter for diagnosing acute liver allograft rejection. World J Gastroenterol 2017; 23(5): 792-799 [PMID: 28223723 DOI: 10.3748/wjg.v23.i5.792] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
133 Guo X, Wang S, Qiu ZG, Dou YL, Liu WL, Yang D, Shen ZQ, Chen ZL, Wang JF, Zhang B, Wang XW, Guo XF, Zhang XL, Jin M, Li JW. Efficient replication of blood-borne hepatitis C virus in human fetal liver stem cells. Hepatology 2017;66:1045-57. [PMID: 28407288 DOI: 10.1002/hep.29211] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
134 Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28-S34. [PMID: 14586892 DOI: 10.1053/jlts.2003.50248] [Cited by in Crossref: 170] [Cited by in F6Publishing: 152] [Article Influence: 10.0] [Reference Citation Analysis]
135 Mariño Z, Londoño M, Forns X. Hepatitis C treatment for patients post liver transplant. Current Opinion in Organ Transplantation 2015;20:251-8. [DOI: 10.1097/mot.0000000000000197] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
136 Doria C, di Francesco F, Marino IR, Ramirez CB, Frank A, Iaria M, Galati SA, Farber JL. c-Kit-positive mast cells in portal tracts cannot be used to distinguish acute cellular rejection from recurrent hepatitis C infection in liver allografts. Transplant Proc 2006;38:3597-600. [PMID: 17175342 DOI: 10.1016/j.transproceed.2006.10.175] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
137 Garcia-Retortillo M, Forns X. Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol. 2004;41:2-10. [PMID: 15246200 DOI: 10.1016/j.jhep.2004.04.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
138 Roos K, Gotthardt D, Giese T, Schnitzler P, Stremmel W, Czock D, Eisenbach C. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy. Liver Transpl 2014;20:1106-17. [PMID: 24890314 DOI: 10.1002/lt.23925] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
139 Davis GL, Krawczynski K, Szabo G. Hepatitis C Virus Infection—Pathobiology and Implications for New Therapeutic Options. Dig Dis Sci 2007;52:857-75. [DOI: 10.1007/s10620-006-9484-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
140 Llovet LP, Sciarrone S, Rodríguez-Tajes S, Montironi C, Mescoli C, Rugge M, Crespo G, Burra P, Forns X, Diaz A, Londoño MC. Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitits after liver transplantation. Gastroenterol Hepatol 2020;43:14-21. [PMID: 31495536 DOI: 10.1016/j.gastrohep.2019.07.006] [Reference Citation Analysis]
141 Massaguer A, Ramírez S, Carrión JA, González P, Sánchez-Tapias JM, Forns X. Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation. Am J Transplant 2007;7:2172-9. [PMID: 17608833 DOI: 10.1111/j.1600-6143.2007.01894.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
142 Sheiner P, Rochon C. Recurrent Hepatitis C After Liver Transplantation: R ECURRENT H EPATITIS C A FTER L IVER T RANSPLANTATION. Mt Sinai J Med 2012;79:190-8. [DOI: 10.1002/msj.21300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
143 Ueda Y, Uemoto S. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients. Transplantation 2016;100:54-60. [PMID: 26335914 DOI: 10.1097/TP.0000000000000860] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
144 Martí J, De la Serna S, Crespo G, Forns X, Ferrer J, Fondevila C, Navasa M, Fuster J, García-Valdecasas JC. Graft and viral outcomes in retransplantation for hepatitis C virus recurrence and HCV primary liver transplantation: a case-control study. Clin Transplant. 2014;28:821-828. [PMID: 24806099 DOI: 10.1111/ctr.12385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
145 Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39:518-531. [PMID: 24461160 DOI: 10.1111/apt.12625] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 13.4] [Reference Citation Analysis]
146 Verna EC, Brown RS. Hepatitis C Virus and Liver Transplantation. Clinics in Liver Disease 2006;10:919-40. [DOI: 10.1016/j.cld.2006.08.012] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 5.0] [Reference Citation Analysis]
147 Tanaka T, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Kurosaki M, Izumi N. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. J Hepatobiliary Pancreat Sci. 2015;22:144-150. [PMID: 25338946 DOI: 10.1002/jhbp.171] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
148 Zignego AL, Gragnani L, Di Pietro E, Solazzo V, Puliti S, Laffi G, Gentilini P. HCV infection, malignancy, and liver transplantation. Transplant Proc 2003;35:1032-3. [PMID: 12947848 DOI: 10.1016/s0041-1345(03)00257-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
149 Keck ZY, Machida K, Lai MM, Ball JK, Patel AH, Foung SK. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr Top Microbiol Immunol. 2008;317:1-38. [PMID: 17990788 DOI: 10.1007/978-3-540-72146-8_1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
150 Walters KA, Joyce MA, Thompson JC, Smith MW, Yeh MM, Proll S, Zhu LF, Gao TJ, Kneteman NM, Tyrrell DL. Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. PLoS Pathog. 2006;2:e59. [PMID: 16789836 DOI: 10.1371/journal.ppat.0020059] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.2] [Reference Citation Analysis]
151 Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012;55:364-72. [PMID: 21953761 DOI: 10.1002/hep.24692] [Cited by in Crossref: 100] [Cited by in F6Publishing: 97] [Article Influence: 10.0] [Reference Citation Analysis]
152 Gao Y, Ren H, Meng F, Li J, Cheung E, Li H, Zhao J, Liu H, Liu Z, Zhang M. Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation. PLoS One 2016;11:e0154419. [PMID: 27123854 DOI: 10.1371/journal.pone.0154419] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
153 Samuel D, Roche B. Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Difficult to manage but essential for success. Journal of Hepatology 2007;46:988-91. [DOI: 10.1016/j.jhep.2007.03.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
154 Bharat A, Narayanan K, Golocheikine A, Steward N, Crippin J, Lisker-Melman M, Shenoy S, Lowell J, Chapman WC, Mohanakumar T. Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis. Transplantation 2007;84:1704-7. [PMID: 18165785 DOI: 10.1097/01.tp.0000295973.31877.7b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
155 Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis. 2003;7:45-66. [PMID: 12691458 DOI: 10.1016/s1089-3261(02)00065-x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 45] [Article Influence: 8.2] [Reference Citation Analysis]
156 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 8.4] [Reference Citation Analysis]
157 Wu SH, Loong CC, Chu CJ, Su CW, Lin CC, Hsia CY, Liu C, Lee SD, Wang YJ, Lee FY, Linb NC, Chen CY, Huang YH, Hou MC. Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation. J Chin Med Assoc 2020;83:18-24. [PMID: 31714442 DOI: 10.1097/JCMA.0000000000000222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
158 Ramirez S, Perez-Del-Pulgar S, Carrion JA, Costa J, Gonzalez P, Massaguer A, Fondevila C, Garcia-Valdecasas JC, Navasa M, Forns X. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am J Transplant. 2009;9:1591-1601. [PMID: 19459796 DOI: 10.1111/j.1600-6143.2009.02666.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
159 Samuel D. I favor therapy for hepatitis C virus recurrence after transplantation. Liver Transplantation 2002;8:S55-8. [DOI: 10.1053/jlts.2002.35857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
160 Sugawara Y, Tamura S, Kokudo N. Antiviral treatment for hepatitis C virus infection after liver transplantation. Hepat Res Treat 2010;2010:475746. [PMID: 21151523 DOI: 10.1155/2010/475746] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Puoti C, Castellacci R, Bellis L, Montagnese F, Corvisieri P, Festuccia F, Mellozzi M, Villani A. Hepatitis C virus RNA quantitation in hepatic veins and peripheral blood in patients with liver cirrhosis: evidence for low level intrahepatic hepatitis C virus replication in advanced liver disease. Digestive and Liver Disease 2002;34:802-7. [DOI: 10.1016/s1590-8658(02)80074-3] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
162 Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, Chalasani N, Yoo H, Rouch D, Liangpunsakul S. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl. 2004;10:404-407. [PMID: 15004768 DOI: 10.1002/lt.20085] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
163 Moonka DK, Kim D, Kapke A, Brown KA, Yoshida A. The Influence of Induction Therapy on Graft and Patient Survival in Patients with and without Hepatitis C after Liver Transplantation. American Journal of Transplantation 2010;10:590-601. [DOI: 10.1111/j.1600-6143.2009.02880.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
164 Schramm F, Soulier E, Royer C, Weitten T, Fafi-Kremer S, Brignon N, Meyer N, Ellero B, Woehl-Jaegle ML, Meyer C. Frequent compartmentalization of hepatitis C virus with leukocyte-related amino acids in the setting of liver transplantation. J Infect Dis. 2008;198:1656-1666. [PMID: 18925843 DOI: 10.1086/592986] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
165 Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant. 2006;6:2232-2237. [PMID: 16869798 DOI: 10.1111/j.1600-6143.2006.01457.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
166 McCaughan GW. New therapies against HCV: expected risks and challenges associated with their use in the liver transplant setting. J Hepatol 2012;57:1361-7. [PMID: 22885390 DOI: 10.1016/j.jhep.2012.07.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
167 Pérez V. Viral hepatitis: historical perspectives from the 20th to the 21st century. Arch Med Res. 2007;38:593-605. [PMID: 17613350 DOI: 10.1016/j.arcmed.2006.09.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
168 Gehrau RC, Mas VR, Villamil FG, Dumur CI, Mehta NK, Suh JL, Maluf DG. MicroRNA signature at the time of clinical HCV recurrence associates with aggressive fibrosis progression post-liver transplantation. Am J Transplant. 2013;13:729-737. [PMID: 23312020 DOI: 10.1111/ajt.12047] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
169 Suda G, Ogawa K, Morikawa K, Sakamoto N. Treatment of hepatitis C in special populations. J Gastroenterol 2018;53:591-605. [PMID: 29299684 DOI: 10.1007/s00535-017-1427-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
170 Hughes MG Jr, Tucker WW, Reddy S, Brier ME, Koch D, McClain CJ, Jonsson CB, Matoba N, Chung D. Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition. PLoS One 2017;12:e0180719. [PMID: 28732019 DOI: 10.1371/journal.pone.0180719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Roche B, Samuel D. Liver transplantation in viral hepatitis: Prevention of recurrence. Best Practice & Research Clinical Gastroenterology 2008;22:1153-69. [DOI: 10.1016/j.bpg.2008.12.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
172 Seifert LL, Heinzow H, Kabar I, Christensen S, Hüsing A, Schmidt HH. Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report. Am J Case Rep 2016;17:605-10. [PMID: 27554644 DOI: 10.12659/ajcr.895839] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
173 Maluf DG, Archer KJ, Villamil F, Stravitz RT, Mas V. Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression. Expert Review of Gastroenterology & Hepatology 2014;4:445-58. [DOI: 10.1586/egh.10.39] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
174 Bernuth S, Grimm D, Vollmar J, Darstein F, Mittler J, Heise M, Hoppe-Lotichius M, Galle PR, Lang H, Zimmermann T. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort. Drug Des Devel Ther 2017;11:2131-8. [PMID: 28744104 DOI: 10.2147/DDDT.S139837] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
175 McTaggart RA, Terrault NA, Vardanian AJ, Bostrom A, Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl. 2004;10:975-985. [PMID: 15390322 DOI: 10.1002/lt.20213] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
176 Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61:S58-68. [PMID: 25443346 DOI: 10.1016/j.jhep.2014.07.012] [Cited by in Crossref: 449] [Cited by in F6Publishing: 416] [Article Influence: 64.1] [Reference Citation Analysis]
177 Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl. 2003;9:S58-S62. [PMID: 14586897 DOI: 10.1053/jlts.2003.50245] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
178 Layden JE, Layden TJ. Viral kinetics of hepatitis C: New insights and remaining limitations: Viral kinetics of hepatitis C: New insights and remaining limitations. Hepatology 2002;35:967-70. [DOI: 10.1053/jhep.2002.32711] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
179 Jothimani D, Venugopal R, Vij M, Rela M. Post liver transplant recurrent and de novo viral infections. Best Pract Res Clin Gastroenterol. 2020;46-47:101689. [PMID: 33158469 DOI: 10.1016/j.bpg.2020.101689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
180 Ramirez S, Perez-del-pulgar S, Carrion JA, Coto-llerena M, Mensa L, Dragun J, Garcia-valdecasas JC, Navasa M, Forns X. Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. Journal of General Virology 2010;91:1183-8. [DOI: 10.1099/vir.0.018929-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
181 Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies: Overview and history of hepatitis C therapies. Hemodialysis International 2018;22:S8-S21. [DOI: 10.1111/hdi.12647] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
182 Bunchorntavakul C, Reddy KR. Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. J Clin Transl Hepatol 2014;2:124-33. [PMID: 26357623 DOI: 10.14218/JCTH.2014.00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
183 Charlton M. Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep 2007;9:23-30. [DOI: 10.1007/s11894-008-0017-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
184 Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat. 2007;14 Suppl 1:89-96. [PMID: 17958649 DOI: 10.1111/j.1365-2893.2007.00920.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 5.8] [Reference Citation Analysis]
185 Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol 2015; 7(3): 616-627 [PMID: 25848486 DOI: 10.4254/wjh.v7.i3.616] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
186 Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol Int 2016;10:749-61. [PMID: 27337961 DOI: 10.1007/s12072-016-9744-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
187 Giard JM, Terrault NA. Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival. Clin Gastroenterol Hepatol 2015;13:2002-4. [PMID: 26192143 DOI: 10.1016/j.cgh.2015.07.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
188 Martin MT, Koppe S. Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis. Transplantation 2017;101:2088-91. [PMID: 28376038 DOI: 10.1097/TP.0000000000001758] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
189 Sprinzl MF, Otto G, Galle PR, Schuchmann M. Hepatitis C virus re-infection: new perspectives. Clin Transplant 2006;20 Suppl 17:117-23. [PMID: 17100711 DOI: 10.1111/j.1399-0012.2006.00610.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
190 Biggins SW, Terrault NA. Management of Recurrent Hepatitis C in Liver Transplant Recipients. Infectious Disease Clinics of North America 2006;20:155-74. [DOI: 10.1016/j.idc.2006.01.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
191 Gehrau R, Maluf D, Archer K, Stravitz R, Suh J, Le N, Mas V. Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients. Mol Med. 2011;17:824-833. [PMID: 21519635 DOI: 10.2119/molmed.2011.00072] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
192 Cisneros L, Londoño MC, Blasco C, Bataller R, Miquel R, Bruguera M, Ginès P, Rimola A. Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. Liver Transpl 2007;13:1017-27. [PMID: 17600343 DOI: 10.1002/lt.21178] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
193 Corradini SG, Micheletta F, Natoli S, Iappelli M, Di Angelantonio E, De Marco R, Elisei W, Siciliano M, Rossi M, Berloco P, Attili AF, Diczfalusy U, Iuliano L. High preoperative recipient plasma 7β-hydroxycholesterol is associated with initial poor graft function after liver transplantation. Liver Transpl 2005;11:1494-504. [DOI: 10.1002/lt.20524] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
194 Dabbous HM, Montasser IF, Sakr MA, Refai R, Sayam M, Abdelmonem A, Sayed H, F Abdelghafar M, Bahaa M, S Elmeteini M. Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far? Hepat Mon. 2016;16:e35339. [PMID: 27330537 DOI: 10.5812/hepatmon.35339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
195 Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, Leroux-Roels G. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology. 2008;48:1761-1768. [PMID: 19030166 DOI: 10.1002/hep.22547] [Cited by in Crossref: 175] [Cited by in F6Publishing: 166] [Article Influence: 14.6] [Reference Citation Analysis]
196 Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10:1363-1377. [PMID: 26563720 DOI: 10.1517/17460441.2015.1094051] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
197 Babcock GJ, Iyer S, Smith HL, Wang Y, Rowley K, Ambrosino DM, Zamore PD, Pierce BG, Molrine DC, Weng Z. High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody. PLoS One 2014;9:e100325. [PMID: 24956119 DOI: 10.1371/journal.pone.0100325] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
198 Ho CM, Hu RH, Lee PH. Perspective of antiviral therapeutics for hepatitis C after liver transplantation. World J Pharmacol 2014; 3(4): 193-198 [DOI: 10.5497/wjp.v3.i4.193] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
199 Knapstein J, Wörns MA, Galle PR, Zimmermann T. Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report. J Med Case Rep. 2014;8:257. [PMID: 25047566 DOI: 10.1186/1752-1947-8-257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
200 Chinnadurai R, Velazquez V, Grakoui A. Hepatic transplant and HCV: a new playground for an old virus. Am J Transplant. 2012;12:298-305. [PMID: 22044693 DOI: 10.1111/j.1600-6143.2011.03812.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
201 Rubín A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol. 2011;35:805-812. [PMID: 21963086 DOI: 10.1016/j.clinre.2011.04.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
202 Manzardo C, Londoño MC, Castells L, Testillano M, Luis Montero J, Peñafiel J, Subirana M, Moreno A, Aguilera V, Luisa González-Diéguez M, Calvo-Pulido J, Xiol X, Salcedo M, Cuervas-Mons V, Manuel Sousa J, Suarez F, Serrano T, Ignacio Herrero J, Jiménez M, Fernandez JR, Giménez C, Del Campo S, Esteban-Mur JI, Crespo G, Moreno A, de la Rosa G, Rimola A, Miro JM; FIPSE LT-HIV investigators. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. Am J Transplant 2018;18:2513-22. [PMID: 29963780 DOI: 10.1111/ajt.14996] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
203 Anand AC, Agarwal SK, Garg HK, Khanna S, Gupta S. Sofosbuvir and Ribavirin for 24 Weeks Is An Effective Treatment Option for Recurrent Hepatitis C Infection After Living Donor Liver Transplantation. J Clin Exp Hepatol 2017;7:165-71. [PMID: 28970701 DOI: 10.1016/j.jceh.2017.06.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
204 Dahari H, Layden-Almer JE, Perelson AS, Layden TJ. Hepatitis C Viral Kinetics in Special Populations. Curr Hepat Rep 2008;7:97-105. [PMID: 19148305 DOI: 10.1007/s11901-008-0022-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
205 McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002;8:S7-S13. [PMID: 12362292 DOI: 10.1053/jlts.2002.35856] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
206 Curry MP. Systematic investigation of elevated transaminases during the third posttransplant month. Liver Transpl. 2013;19 Suppl 2:S17-S22. [PMID: 24019297 DOI: 10.1002/lt.23737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
207 Jackson WE, Hanouneh M, Apfel T, Alkhouri N, John BV, Zervos X, Zein NN, Hanouneh IA. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience. Clin Transplant. 2016;30:709-713. [PMID: 27019204 DOI: 10.1111/ctr.12738] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
208 Charlton M, Gane E, Manns MP, Brown RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, Mchutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA. Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. Gastroenterology 2015;148:108-17. [DOI: 10.1053/j.gastro.2014.10.001] [Cited by in Crossref: 274] [Cited by in F6Publishing: 239] [Article Influence: 45.7] [Reference Citation Analysis]
209 Mensa L, Crespo G, Gastinger MJ, Kabat J, Pérez-del-Pulgar S, Miquel R, Emerson SU, Purcell RH, Forns X. Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology 2011;53:1436-45. [PMID: 21294144 DOI: 10.1002/hep.24110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
210 Canini L, DebRoy S, Mariño Z, Conway JM, Crespo G, Navasa M, D'Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, Dahari H. Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Antivir Ther 2015;20:149-55. [PMID: 24912382 DOI: 10.3851/IMP2806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
211 Barik S. Molecular Interactions between Pathogens and the Circadian Clock. Int J Mol Sci 2019;20:E5824. [PMID: 31756974 DOI: 10.3390/ijms20235824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
212 Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014;61:S120-S131. [PMID: 25443340 DOI: 10.1016/j.jhep.2014.07.020] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
213 Oo YH, Dudley T, Nightingale P, Haydon G, Mutimer D. Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation. Liver Transpl 2008;14:81-7. [DOI: 10.1002/lt.21387] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
214 Araujo A, Valenzuela-Granados V, Lopes AB, Michalczuk MT, Mantovani A, Alvares-da-Silva MR. Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience. Ann Hepatol 2019;18:450-5. [PMID: 31028014 DOI: 10.1016/j.aohep.2018.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
215 Limaye AR, Firpi RJ. Management of recurrent hepatitis C infection after liver transplantation. Clin Liver Dis 2011;15:845-58. [PMID: 22032532 DOI: 10.1016/j.cld.2011.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
216 Ponziani FR, Annicchiarico EB, Siciliano M, D’Aversa F, Pompili M, Gasbarrini A. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. World J Gastroenterol 2013; 19(21): 3255-3262 [PMID: 23745027 DOI: 10.3748/wjg.v19.i21.3255] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
217 Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, Navasa M, Rimola A, Rodés J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003;39:389-396. [PMID: 12927925 DOI: 10.1016/s0168-8278(03)00310-6] [Cited by in Crossref: 231] [Cited by in F6Publishing: 51] [Article Influence: 13.6] [Reference Citation Analysis]
218 Ruvo ND, Cucchetti A, Lauro A, Masetti M, Benedetto FD, Cautero N, Barba GL, Dazzi A, Francesco FD, Molteni G, Romano A, Ramacciato G, Risaliti A, Pinna AD. Minimization of immunosuppression with thymoglobuline pre-treatment and HCV recurrence in liver transplantation. Clin Transplant 2005;19:255-8. [DOI: 10.1111/j.1399-0012.2005.00333.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
219 Funk GA, Gosert R, Hirsch HH. Viral dynamics in transplant patients: implications for disease. The Lancet Infectious Diseases 2007;7:460-72. [DOI: 10.1016/s1473-3099(07)70159-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
220 Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis. 2003;7:585-602. [PMID: 14509528 DOI: 10.1016/s1089-3261(03)00046-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
221 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
222 Berge E, Otón E, Reina Z, Díaz L, Márquez A, Cejas L, Acosta S, Pérez F. Predictors of Poor Prognosis in Recurrent Hepatitis C After Liver Transplantation. Transplant Proc 2016;48:2997-9. [PMID: 27932129 DOI: 10.1016/j.transproceed.2016.07.043] [Reference Citation Analysis]
223 Neff GW, Kemmer N, Kaiser T, Zacharias V, Majoras N, Safdar K. Outcomes in adult and pediatric liver transplantation among various ethnic groups. Transplant Proc 2007;39:3204-6. [PMID: 18089354 DOI: 10.1016/j.transproceed.2007.09.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
224 Melum E, Friman S, Bjøro K, Rasmussen A, Isoniemi H, Gjertsen H, Bäckman L, Oksanen A, Olausson M, Duraj FF, Ericzon B. Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma. Journal of Hepatology 2007;47:777-83. [DOI: 10.1016/j.jhep.2007.06.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
225 Lagging M, Wejstål R, Uhnoo I, Gerdén B, Fischler B, Friman S, Josephson F, Karlström O, Sangfelt P, Schvarz R, Weiland O, For The Swedish Consensus Group, Lagging M, Wejstål R, Uhnoo I, Gerdén B, Fischler B, Friman S, Josephson F, Karlström O, Sangfelt P, Schvarz R, Weiland O, For The Swedish Consensus Group. Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations. Scandinavian Journal of Infectious Diseases 2009;41:389-402. [DOI: 10.1080/00365540902998271] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
226 Lenci I, Bosa A, Milana M, Baiocchi L, Antonucci FP, Aragri M, Ceccherini-Silberstein F, Perno CF, Tisone G, Angelico M. Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation. Dig Dis Sci 2017;62:2193-5. [PMID: 28500586 DOI: 10.1007/s10620-017-4594-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
227 Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol. 2010;199:1-10. [PMID: 19902246 DOI: 10.1007/s00430-009-0131-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
228 Crespo G, Carrión JA, Coto-Llerena M, Mariño Z, Lens S, Pérez-Del-Pulgar S, García-Retortillo M, Miquel R, Bosch J, Navasa M, Forns X. Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol 2013;48:762-9. [PMID: 23011083 DOI: 10.1007/s00535-012-0680-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
229 Fu H, Dong J, Sun Z, Zhang X, Yu A, Chen G, Li W. Efficacy and safety of sofosbuvir-containing regimens in patients with chronic hepatitis C virus infection after liver transplantation: a meta-analysis. Ann Transl Med 2020;8:648. [PMID: 32566585 DOI: 10.21037/atm-20-3074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Micheloud D, Salcedo M, Bañares R, Rincón D, Lorente R, Muñoz-Fernández MA, Resino S. Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence. Transpl Infect Dis 2009;11:183-8. [PMID: 19254326 DOI: 10.1111/j.1399-3062.2009.00370.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
231 Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-78. [PMID: 11690716 DOI: 10.1016/s0168-8278(01)00179-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
232 Heidrich B, Pischke S, Helfritz FA, Mederacke I, Kirschner J, Schneider J, Raupach R, Jäckel E, Barg-hock H, Lehner F, Klempnauer J, von Hahn T, Cornberg M, Manns MP, Ciesek S, Wedemeyer H. Hepatitis C virus core antigen testing in liver and kidney transplant recipients. J Viral Hepat 2014;21:769-79. [DOI: 10.1111/jvh.12204] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
233 Hori T, Onishi Y, Kamei H, Kurata N, Ishigami M, Ishizu Y, Ogura Y. Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Ann Gastroenterol 2016;29:454-9. [PMID: 27708510 DOI: 10.20524/aog.2016.0069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
234 Berenguer M, Agarwal K, Burra P, Manns M, Samuel D. The road map toward an hepatitis C virus-free transplant population. Am J Transplant 2018;18:2409-16. [PMID: 29935050 DOI: 10.1111/ajt.14976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
235 Koutsoudakis G, Pérez-del-Pulgar S, González P, Crespo G, Navasa M, Forns X. A Gaussia luciferase cell-based system to assess the infection of cell culture- and serum-derived hepatitis C virus. PLoS One 2012;7:e53254. [PMID: 23300900 DOI: 10.1371/journal.pone.0053254] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
236 Saxena V, Terrault N. Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients. Clin Liver Dis 2015;19:669-88, vi. [PMID: 26466655 DOI: 10.1016/j.cld.2015.06.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
237 Novelli G, Rossi M, Morabito V, Ferretti G, Pretagostini R, Ruberto F, Pugliese F, Guglielmo N, Berloco P. Management of Hepatitis C Virus Infection in Liver Transplantation with Adacolumn Apheresis. Transplantation Proceedings 2012;44:1946-52. [DOI: 10.1016/j.transproceed.2012.06.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
238 Longerich T, Schirmacher P. General aspects and pitfalls in liver transplant pathology. Clin Transplant 2006;20 Suppl 17:60-8. [PMID: 17100703 DOI: 10.1111/j.1399-0012.2006.00602.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
239 Tanimine N, Tanaka Y, Abe T, Piao J, Chayama K, Ohdan H. Functional Behavior of NKp46-Positive Intrahepatic Natural Killer Cells Against Hepatitis C Virus Reinfection After Liver Transplantation. Transplantation 2016;100:355-64. [PMID: 26714120 DOI: 10.1097/TP.0000000000001031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
240 Feliu A, Carrión JA, Massaguer A, Martínez-Bauer E, García-Retortillo M, González P, Costa J, Sánchez-Tapias JM, Forns X. Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. J Viral Hepat. 2006;13:544-551. [PMID: 16901285 DOI: 10.1111/j.1365-2893.2006.00714.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
241 Gwak GY. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Patients with Decompensated Cirrhosis]. Korean J Gastroenterol 2016;67:137-41. [PMID: 26996183 DOI: 10.4166/kjg.2016.67.3.137] [Reference Citation Analysis]
242 Hsu SH, Yeh ML, Wang SN. New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol. 2013;2013:890517. [PMID: 23710205 DOI: 10.1155/2013/890517] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
243 Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest. 2009;119:3226-3235. [PMID: 19805910 DOI: 10.1172/jci38374] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis]
244 Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol. 2005;42:448-456. [PMID: 15763325 DOI: 10.1016/j.jhep.2005.01.011] [Cited by in Crossref: 116] [Cited by in F6Publishing: 102] [Article Influence: 7.3] [Reference Citation Analysis]
245 McCarty TR, Lim JK. Developing therapies to treat hepatitis C infection in post-liver transplant recipients. Expert Opin Pharmacother 2017;18:165-74. [PMID: 28024124 DOI: 10.1080/14656566.2016.1276564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
246 Nellore A, Fishman JA. NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis. 2011;52:369-377. [PMID: 21217184 DOI: 10.1093/cid/ciq156] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
247 Heil EL, Hynicka LM, Kottilil S, Tang L. What does the pharmacological future of treating chronic hepatitis C look like? Expert Rev Clin Pharmacol 2015;8:605-22. [PMID: 26289223 DOI: 10.1586/17512433.2015.1074859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
248 Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, Giachetti C, Busch MP. Viral and host factors in early hepatitis C virus infection. Hepatology. 2005;42:86-92. [PMID: 15954090 DOI: 10.1002/hep.20742] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
249 Ponziani FR, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, Burra P, Miglioresi L. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. Dig Liver Dis. 2014;46:440-445. [PMID: 24635906 DOI: 10.1016/j.dld.2014.01.157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
250 Mao JX, Guo WY, Guo M, Liu C, Teng F, Ding GS. Acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients. Hepatol Int 2020;14:347-61. [PMID: 32140981 DOI: 10.1007/s12072-020-10022-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
251 Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol. 2005;43:53-59. [PMID: 15876467 DOI: 10.1016/j.jhep.2005.02.015] [Cited by in Crossref: 125] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
252 Carrión JA, Fernández-Varo G, Bruguera M, García-Pagán JC, García-Valdecasas JC, Pérez-Del-Pulgar S, Forns X, Jiménez W, Navasa M. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology. 2010;138:147-158.e1. [PMID: 19786026 DOI: 10.1053/j.gastro.2009.09.047] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
253 Bharat A, Barros F, Narayanan K, Borg B, Lisker-Melman M, Shenoy S, Lowell J, Crippin J, Chapman W, Mohanakumar T. Characterization of virus-specific T-cell immunity in liver allograft recipients with HCV-induced cirrhosis. Am J Transplant 2008;8:1214-20. [PMID: 18522547 DOI: 10.1111/j.1600-6143.2008.02248.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
254 Dahari H, Feliu A, Garcia-Retortillo M, Forns X, Neumann AU. Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol. 2005;42:491-498. [PMID: 15763335 DOI: 10.1016/j.jhep.2004.12.017] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
255 Gedaly R, Clifford TM, McHugh PP, Jeon H, Johnston TD, Ranjan D. Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey. Transpl Int. 2008;21:867-872. [PMID: 18498313 DOI: 10.1111/j.1432-2277.2008.00699.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
256 Carrión JA. Utilidad del Fibroscan® para evaluar la fibrosis hepática. Gastroenterología y Hepatología 2009;32:415-23. [DOI: 10.1016/j.gastrohep.2009.01.178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
257 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 113.0] [Reference Citation Analysis]
258 Mariño Z, Carrión JA, Bedini JL, Crespo G, Martínez SM, Sánchez-tapias JM, Forns X, Navasa MA. Evaluation of a portable hemoglobinometer (HemoCue) to control anemia in hepatitis C liver transplant recipients undergoing antiviral therapy: . European Journal of Gastroenterology & Hepatology 2011;23:942-7. [DOI: 10.1097/meg.0b013e328348f9c2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
259 Llovet L, Rodríguez-tajes S, Londoño M. Tratamiento de la hepatitis C en el pre- y postrasplante hepático. Gastroenterología y Hepatología 2016;39:344-51. [DOI: 10.1016/j.gastrohep.2015.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
260 Righi E, Londero A, Carnelutti A, Baccarani U, Bassetti M. Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol 2015; 21(38): 10760-10775 [PMID: 26478668 DOI: 10.3748/wjg.v21.i38.10760] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
261 Chin JL, Nicholas RM, Russell J, Carr M, Connell J, Stewart S, McCormick PA. Spontaneous clearance of hepatitis C infection after liver transplantation from IL28B rs12979860 CC donors. Eur J Gastroenterol Hepatol. 2012;24:1110-1112. [PMID: 22664940 DOI: 10.1097/meg.0b013e3283554291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
262 Berenguer M. Hepatitis C after liver transplantation: risk factors, outcomes, and treatment: . Current Opinion in Organ Transplantation 2005;10:81-9. [DOI: 10.1097/01.mot.0000161761.40866.12] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
263 European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236. [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025] [Cited by in Crossref: 814] [Cited by in F6Publishing: 766] [Article Influence: 135.7] [Reference Citation Analysis]
264 Berenguer M. Viral hepatitis after liver transplantation. Hepatology Research 2007;37:S279-86. [DOI: 10.1111/j.1872-034x.2007.00198.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
265 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433-485. [PMID: 26597456 DOI: 10.1016/j.jhep.2015.10.006] [Cited by in Crossref: 390] [Cited by in F6Publishing: 292] [Article Influence: 65.0] [Reference Citation Analysis]
266 Lin L, Libbrecht L, Verbeeck J, Verslype C, Roskams T, van Pelt J, Van Ranst M, Fevery J. Quantitation of replication of the HCV genome in human livers with end-stage cirrhosis by strand-specific real-time RT-PCR assays: methods and clinical relevance. J Med Virol 2009;81:1569-75. [PMID: 19626615 DOI: 10.1002/jmv.21510] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
267 Mariño Z, Mensa L, Crespo G, Miquel R, Bruguera M, Pérez-Del-Pulgar S, Bosch J, Forns X, Navasa M. Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. J Hepatol 2014;61:270-7. [PMID: 24703854 DOI: 10.1016/j.jhep.2014.03.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
268 Watt KD, Burak K, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner EL, Yoshida EM; Canadian Transplant Hepatology Outcomes Research Network. Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol 2006;20:725-34. [PMID: 17111055 DOI: 10.1155/2006/238218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
269 Chen T, Terrault NA. Perspectives on treating hepatitis C infection in the liver transplantation setting. Curr Opin Organ Transplant. 2016;21:111-119. [PMID: 26927201 DOI: 10.1097/mot.0000000000000288] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
270 Carrión JA, Torres F, Crespo G, Miquel R, García-valdecasas J, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010;51:23-34. [DOI: 10.1002/hep.23240] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 8.4] [Reference Citation Analysis]
271 El-Ghitany EM, Farghaly AG, Hashish MH. Occult hepatitis B virus infection among hepatitis C virus seropositive and seronegative blood donors in Alexandria, Egypt. J Egypt Public Health Assoc. 2013;88:8-13. [PMID: 23528526 DOI: 10.1097/01.epx.0000422774.29308.b3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
272 Rimola A, Londoño MC, Guevara G, Bruguera M, Navasa M, Forns X, García-Retortillo M, García-Valdecasas JC, Rodes J. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004;78:686-91. [PMID: 15371669 DOI: 10.1097/01.tp.0000128913.09774.ce] [Cited by in Crossref: 73] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
273 Lucidi V, Gustot T, Moreno C, Donckier V. Liver transplantation in the context of organ shortage: toward extension and restriction of indications considering recent clinical data and ethical framework. Curr Opin Crit Care 2015;21:163-70. [PMID: 25692807 DOI: 10.1097/MCC.0000000000000186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
274 Fernández Carrillo C, Crespo G, de la Revilla J, Castells L, Buti M, Montero JL, Fábrega E, Fernández I, Serrano-Millán C, Hernández V, Calleja JL, Londoño MC. Successful Continuation of HCV Treatment After Liver Transplantation. Transplantation 2017;101:1009-12. [PMID: 27906834 DOI: 10.1097/TP.0000000000001596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
275 Citores MJ, Pérez-pulgar S, Duca A, Crespo G, de la Fuente S, Vilches C, Navasa M, Cuervas-mons V. Rapidity of fibrosis progression in liver transplant recipients with recurrent hepatitis C is influenced by toll-like receptor 3 polymorphism. Clin Transplant 2016;30:810-8. [DOI: 10.1111/ctr.12754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
276 Sajjad EA, Radkowski M, Perkowska-Ptasińska A, Pacholczyk M, Durlik M, Fedorowicz M, Pietrzak R, Ziarkiewicz-Wróblewska B, Włodarski P, Malejczyk J. Negative Correlation Between Hepatitis C Virus (HCV) and Let-7 MicroRNA Family in Transplanted Livers: The Role of rs868 Single-Nucleotide Polymorphism. Ann Transplant 2017;22:638-45. [PMID: 29061957 DOI: 10.12659/aot.905540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
277 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
278 Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, Gopher J, Buchnick R, Kovjazin R, Rosenthal-Galili Z, Aviel S, Ilan E, Shoshany Y, Neville L, Waisman T, Ben-Moshe O, Kischitsky A, Foung SK, Keck ZY, Pappo O, Eid A, Jurim O, Zamir G, Galun E, Dagan S. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006;80:2654-64. [PMID: 16501075 DOI: 10.1128/JVI.80.6.2654-2664.2006] [Cited by in Crossref: 78] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
279 Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation. SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol 2012;18 Suppl:S1-32. [PMID: 23006491 DOI: 10.4103/1319-3767.101155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
280 Ocaña L, Cos J, Quer J, Bilbao I, Palou E, Parra R, Sauleda S, Esteban JI, Guàrdia J, Massuet LI, Margarit C. Analysis of INF-gamma, TNF-alpha and dendritic cells to predict hepatitis C virus recurrence in liver transplant patients. Transplant Proc 2005;37:3951-6. [PMID: 16386594 DOI: 10.1016/j.transproceed.2005.09.183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
281 Ramírez S, Pérez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 2008;14 Suppl 2:S27-S35. [PMID: 18825723 DOI: 10.1002/lt.21644] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
282 Shekhtman L, Navasa M, Sansone N, Crespo G, Subramanya G, Chung TL, Cardozo-Ojeda EF, Pérez-Del-Pulgar S, Perelson AS, Cotler SJ, Forns X, Uprichard SL, Dahari H. Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance. Elife 2021;10:e65297. [PMID: 34730511 DOI: 10.7554/eLife.65297] [Reference Citation Analysis]
283 Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, van der Laan LJ. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology. 2006;131:1452-1462. [PMID: 17101321 DOI: 10.1053/j.gastro.2006.08.027] [Cited by in Crossref: 80] [Cited by in F6Publishing: 82] [Article Influence: 5.3] [Reference Citation Analysis]
284 Russo MW, Narang T, Eskind L, Hayes D, Casingal V, Purdum PP, Hanson JS, Ahrens W, Norton J, Bonkovsky H. Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection. Dig Dis Sci 2013;58:3010-6. [PMID: 23812862 DOI: 10.1007/s10620-013-2749-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
285 Cameron AM, Busuttil RW. The status of liver transplantation for hepatitis C. Expert Opinion on Biological Therapy 2006;6:993-1002. [DOI: 10.1517/14712598.6.10.993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
286 López-Labrador FX, Bracho MA, Berenguer M, Coscollà M, Rayón JM, Prieto M, Carrasco D, Gómez MD, Moya A, González-Candelas F. Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation. J Viral Hepat 2006;13:104-15. [PMID: 16436128 DOI: 10.1111/j.1365-2893.2005.00670.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
287 Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C. Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis. Journal of Hepatology 2006;45:127-43. [DOI: 10.1016/j.jhep.2006.05.001] [Cited by in Crossref: 129] [Cited by in F6Publishing: 108] [Article Influence: 8.6] [Reference Citation Analysis]
288 D'Ambrosio R, Aghemo A, Colombo M. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. Expert Opin Drug Saf 2015;14:473-84. [PMID: 25645644 DOI: 10.1517/14740338.2015.1009035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
289 Hughes MG Jr, Rosen HR. Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl 2009;15:1395-411. [PMID: 19877210 DOI: 10.1002/lt.21866] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
290 Schramm F, Moenne-Loccoz R, Fafi-Kremer S, Soulier E, Royer C, Weitten T, Brignon N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Doffoel M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E. [Study of hepatitis C virus leukotropism by characterization of viral quasispecies in the liver transplantation setting]. Pathol Biol (Paris) 2008;56:487-91. [PMID: 18842359 DOI: 10.1016/j.patbio.2008.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
291 Charlton M. Recurrence of hepatitis C infection: Where are we now? Liver Transpl 2005;11:S57-62. [DOI: 10.1002/lt.20597] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
292 Xu M, Brown RS. Liver Transplantation for the Referring Physician. Clinics in Liver Disease 2015;19:135-53. [DOI: 10.1016/j.cld.2014.09.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
293 Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ. Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl 2016;22:287-97. [PMID: 26437376 DOI: 10.1002/lt.24349] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
294 Silini E, Belli L, Brambilla S, Foti L, Gritti C, Lisa A, Alberti AB, Vinci M, De Carlis L, Rondinara G, Pinzello G. Sequence variation in the hypervariable region 1 of hepatitis C virus and posttransplantation recurrent hepatitis. Liver Transpl 2003;9:1040-7. [PMID: 14526398 DOI: 10.1053/jlts.2003.50180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
295 Ciccorossi P, Maina AM, Oliveri F, Petruccelli S, Leandro G, Colombatto P, Moriconi F, Mosca F, Filipponi F, Bonino F, Brunetto MR. Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. Liver Int 2007;27:612-9. [DOI: 10.1111/j.1478-3231.2007.01459.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
296 Berenguer M. Management of Hepatitis C Virus in the Transplant Patient. Clinics in Liver Disease 2007;11:355-76. [DOI: 10.1016/j.cld.2007.04.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
297 Mutimer D. Understanding the switchbacks: The impact of direct antivirals on the minimization of hepatitis C virus recurrence after transplantation. Liver Transpl 2012;18:S47-51. [DOI: 10.1002/lt.23533] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
298 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 749] [Article Influence: 301.7] [Reference Citation Analysis]
299 Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, Hassanain M, Paraskevas S, Chaudhury P, Tchervenkov JI. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience. HPB (Oxford). 2013;15:724-731. [PMID: 23490176 DOI: 10.1111/hpb.12041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
300 Berenguer M. [Management of hepatitis C virus infection in liver transplantation]. Gastroenterol Hepatol 2006;29:422-7. [PMID: 16938259 DOI: 10.1157/13091455] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
301 Lengyel G, Tulassay Z. [Treatment of recurrent hepatitis C virus infection after liver transplantation]. Orv Hetil 2007;148:1875-81. [PMID: 17905682 DOI: 10.1556/OH.2007.28217] [Reference Citation Analysis]
302 Jiménez-Pérez M, González-Grande R, Rando-Muñoz FJ. Management of recurrent hepatitis C virus after liver transplantation. World J Gastroenterol 2014; 20(44): 16409-16417 [PMID: 25469009 DOI: 10.3748/wjg.v20.i44.16409] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
303 Germani G, Tsochatzis E, Papastergiou V, Burroughs AK. HCV in liver transplantation. Semin Immunopathol. 2013;35:101-110. [PMID: 22829333 DOI: 10.1007/s00281-012-0329-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
304 Graziadei IW, Zoller HM, Schloegl A, Nachbaur K, Pfeiffer KP, Mark W, Mikuz G, Pratschke J, Margreiter R, Vogel W. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl. 2012;18:671-679. [PMID: 22298465 DOI: 10.1002/lt.23402] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
305 Berenguer M, Ortíz-Cantó C, Abellán JJ, Aguilera V, Rubín A, Prieto M, López-Labrador FX. Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes. J Clin Virol 2012;53:231-8. [PMID: 22222052 DOI: 10.1016/j.jcv.2011.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
306 Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system? J Biosci. 2003;28:287-304. [PMID: 12734407 DOI: 10.1007/bf02970148] [Cited by in Crossref: 64] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
307 Bodro M, Sanclemente G, Crespo G, Linares L, Marcos MA, Marco F, Miquel R, Forns X, Navasa M, Moreno A. Severe Hepatitis C Recurrence as a Risk Factor for Opportunistic Infections in Liver Transplant Recipients. Transplant Proc 2018;50:1437-43. [PMID: 29880367 DOI: 10.1016/j.transproceed.2018.02.081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
308 Rubín A, Berenguer M. [Liver transplantation: personalized immunosuppression in patients with hepatitis C virus infection and hepatocellular carcinoma]. Gastroenterol Hepatol 2013;36:48-57. [PMID: 22578313 DOI: 10.1016/j.gastrohep.2012.03.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
309 Feliu A, Gay E, García-Retortillo M, Saiz JC, Forns X. Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver Transpl. 2004;10:1131-1139. [PMID: 15350003 DOI: 10.1002/lt.20206] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.7] [Reference Citation Analysis]
310 Mariño Z, Crespo G, D'Amato M, Brambilla N, Giacovelli G, Rovati L, Costa J, Navasa M, Forns X. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J Hepatol 2013;58:415-20. [PMID: 23063567 DOI: 10.1016/j.jhep.2012.09.034] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
311 Canivet C, Böhler T, Galvani S, Péron J, Muscari F, Alric L, Barange K, Salvayre R, Negre-salvayre A, Durand D, Suc B, Izopet J, Thomsen M, Rostaing L, Kamar N. In vitro mitogen-stimulated T-cell from hepatitis C virus-positive liver transplantation candidates, increases T-cell activation markers and T-cell proliferation. Transplant Immunology 2008;19:112-9. [DOI: 10.1016/j.trim.2008.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
312 Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol 2015; 7(12): 1606-1616 [PMID: 26140081 DOI: 10.4254/wjh.v7.i12.1606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
313 Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, Jestin JL, Brown RJ, McKeating JA, Rey FA, Ball JK, Krey T. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 2013;58:932-9. [PMID: 23553604 DOI: 10.1002/hep.26430] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
314 Lin CC, Kabiling C, Chen CL, Lin YH, Liu YW, Wang CC, Hu TH, Chiu KW. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients. Transplantation. 2014;97 Suppl 8:S47-S53. [PMID: 24849835 DOI: 10.1097/01.tp.0000446277.36181.e7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
315 Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132:1746-1756. [PMID: 17484872 DOI: 10.1053/j.gastro.2007.03.041] [Cited by in Crossref: 287] [Cited by in F6Publishing: 240] [Article Influence: 20.5] [Reference Citation Analysis]
316 Ichikawa T, Nakao K, Hamasaki K, Honda T, Shibata H, Akahoshi M, Eguchi S, Takatsuki M, Kanematsu T, Eguchi K. Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation. World J Gastroenterol 2007; 13(30): 4149-4151 [PMID: 17696240 DOI: 10.3748/wjg.v13.i30.4149] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
317 Lucey M. Induction immunosuppression in hepatitis C virus–infected liver transplant recipients. Liver Transplantation 2002;8:S44-6. [DOI: 10.1053/jlts.2002.35854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
318 Yoshizawa A, Takada Y, Fujimoto Y, Koshiba T, Haga H, Nabeshima S, Uemoto S. Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C. Am J Transplant. 2006;6:2812-2816. [PMID: 16939511 DOI: 10.1111/j.1600-6143.2006.01531.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
319 Bes M, Sauleda S, Casamitjana N, Piron M, Campos-varela I, Quer J, Cubero M, Puig L, Guardia J, Esteban JI. Reversal of nonstructural protein 3-specific CD4+ T cell dysfunction in patients with persistent hepatitis C virus infection: Reversal of HCV-specific CD4+ T cell tolerance. Journal of Viral Hepatitis 2012;19:283-94. [DOI: 10.1111/j.1365-2893.2011.01549.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
320 Londoño MC, Crespo G, Forns X. Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. Curr Opin Organ Transplant 2013;18:271-8. [PMID: 23665543 DOI: 10.1097/MOT.0b013e3283614aca] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
321 Roche B, Samuel D. Aspects of hepatitis C virus infection relating to liver transplantation: . European Journal of Gastroenterology & Hepatology 2006;18:313-20. [DOI: 10.1097/00042737-200604000-00002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
322 Bojito-Marrero L, Pyrsopoulos N. Hepatitis B and Hepatitis C Reactivation in the Biologic Era. J Clin Transl Hepatol. 2014;2:240-246. [PMID: 26355300 DOI: 10.14218/jcth.2014.00033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
323 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-194. [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001] [Cited by in Crossref: 712] [Cited by in F6Publishing: 648] [Article Influence: 142.4] [Reference Citation Analysis]
324 . EASL Recommendations on Treatment of Hepatitis C 2014. Journal of Hepatology 2014;61:373-95. [DOI: 10.1016/j.jhep.2014.05.001] [Cited by in Crossref: 128] [Cited by in F6Publishing: 134] [Article Influence: 18.3] [Reference Citation Analysis]
325 Romagnoli R, Martini S, Tandoi F, Dell Olio D, Magistroni P, Bertinetto FE, Dametto E, Rizzetto M, Salizzoni M, Amoroso A. Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers. Transpl Int 2016;29:1070-84. [DOI: 10.1111/tri.12795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
326 Carrión JA, Navasa M, Forns X. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol. 2010;53:962-970. [PMID: 20800307 DOI: 10.1016/j.jhep.2010.06.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
327 Mah A, Wright A. Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. Curr Infect Dis Rep. 2016;18:4. [PMID: 26743200 DOI: 10.1007/s11908-015-0514-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
328 Joshi D, Pinzani M, Carey I, Agarwal K. Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. Nat Rev Gastroenterol Hepatol. 2014;11:710-721. [PMID: 25023032 DOI: 10.1038/nrgastro.2014.114] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
329 Duvoux C, Firpi R, Grazi GL, Levy G, Renner E, Villamil F. Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor. Transpl Int. 2013;26:358-372. [PMID: 23413991 DOI: 10.1111/tri.12065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
330 Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14 Suppl 2:S36-S44. [PMID: 18825724 DOI: 10.1002/lt.21646] [Cited by in Crossref: 203] [Cited by in F6Publishing: 171] [Article Influence: 16.9] [Reference Citation Analysis]
331 Roche B, Samuel D. Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? The answer is no. Liver Transpl 2011;17:488-91. [DOI: 10.1002/lt.22297] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
332 Schiano TD, Gutierrez JA, Walewski JL, Fiel MI, Cheng B, Bodenheimer H, Thung SN, Chung RT, Schwartz ME, Bodian C, Branch AD. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005;42:1420-8. [DOI: 10.1002/hep.20947] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
333 Mawardi M, Aba Alkhail F, Katada K, Levstik M, Quan D, Wall W, Marotta P, Hernandezalejandro R. The clinical consequences of utilizing donation after cardiac death liver grafts into hepatitis C recipients. Hepatol Int 2011;5:830-3. [DOI: 10.1007/s12072-010-9242-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
334 Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del-Pulgar S, García-Valdecasas JC, Navasa M, Forns X. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol. 2009;50:719-728. [PMID: 19217183 DOI: 10.1016/j.jhep.2008.11.015] [Cited by in Crossref: 151] [Cited by in F6Publishing: 127] [Article Influence: 11.6] [Reference Citation Analysis]
335 Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, Eren R, Dagan S, Graham N, Williams PV. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 2006;12:1381-1389. [PMID: 16933235 DOI: 10.1002/lt.20876] [Cited by in Crossref: 92] [Cited by in F6Publishing: 78] [Article Influence: 6.1] [Reference Citation Analysis]
336 Kitchens WH, Yeh H, Markmann JF. Hepatic retransplant: what have we learned? Clin Liver Dis. 2014;18:731-751. [PMID: 25017086 DOI: 10.1016/j.cld.2014.05.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
337 Mccaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. Journal of Hepatology 2004;40:368-74. [DOI: 10.1016/j.jhep.2004.01.014] [Cited by in Crossref: 79] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
338 Obed A, Jarrad A, Bashir A, Moog G. Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report. Am J Case Rep 2016;17:357-9. [PMID: 27230979 DOI: 10.12659/ajcr.896810] [Reference Citation Analysis]
339 Koutsoudakis G, Perez-del-Pulgar S, Coto-Llerena M, Gonzalez P, Dragun J, Mensa L, Crespo G, Navasa M, Forns X. Cell culture replication of a genotype 1b hepatitis C virus isolate cloned from a patient who underwent liver transplantation. PLoS One 2011;6:e23587. [PMID: 21887279 DOI: 10.1371/journal.pone.0023587] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
340 Tronina O, Ślubowska K, Mikołajczyk-Korniak N, Komuda-Leszek E, Wieczorek-Godlewska R, Łągiewska B, Pacholczyk M, Lisik W, Kosieradzki M, Durlik M. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. Transplant Proc 2017;49:1409-18. [PMID: 28736015 DOI: 10.1016/j.transproceed.2017.01.077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Zanaga LP, Vigani AG, Angerami RN, Giorgetti A, Escanhoela CA, Ataíde EC, Boin IF, Stucchi RS. Survival benefits of interferon-based therapy in patients with recurrent hepatitis C after orthotopic liver transplantation. Braz J Med Biol Res 2017;50:e5540. [PMID: 28076451 DOI: 10.1590/1414-431X20165540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
342 Ichikawa T, Nakao K, Miyaaki H, Eguchi S, Takatsuki M, Fujimito M, Akiyama M, Miuma S, Ozawa E, Shibata H, Takeshita S, Kanematsu T, Eguchi K. Hepatitis C virus kinetics during the first phase of pegylated interferon-alpha-2b with ribavirin therapy in patients with living donor liver transplantation. Hepatol Res 2009;39:856-64. [PMID: 19624776 DOI: 10.1111/j.1872-034X.2009.00524.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
343 Fung J. Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol 2015; 7(24): 2543-2550 [PMID: 26523206 DOI: 10.4254/wjh.v7.i24.2543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
344 Filipec Kanizaj T, Kunac N. Hepatitis C: New challenges in liver transplantation. World J Gastroenterol 2015; 21(19): 5768-5777 [PMID: 26019441 DOI: 10.3748/wjg.v21.i19.5768] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
345 Blasco A, Forns X, Carrión JA, García-Pagán JC, Gilabert R, Rimola A, Miquel R, Bruguera M, García-Valdecasas JC, Bosch J. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43:492-499. [PMID: 16496308 DOI: 10.1002/hep.21090] [Cited by in Crossref: 220] [Cited by in F6Publishing: 198] [Article Influence: 14.7] [Reference Citation Analysis]
346 Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl. 2003;9:1129-1144. [PMID: 14586872 DOI: 10.1053/jlts.2003.50261] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
347 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association 2020;119:1135-57. [DOI: 10.1016/j.jfma.2020.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 24.0] [Reference Citation Analysis]
348 De Ruvo N, Cucchetti A, Lauro A, Masetti M, Cautero N, Di Benedetto F, Dazzi A, Del Gaudio M, Ravaioli M, Di Francesco F. Preliminary results of a “prope” tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation. 2005;80:8-12. [PMID: 16003226 DOI: 10.1097/01.tp.0000164349.54297.95] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
349 Fernández-Carrillo C, Coto-Llerena M, González P, Crespo G, Mensa L, Caro-Pérez N, Gambato M, Navasa M, Forns X, Pérez-del-Pulgar S. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation. J Clin Virol 2014;61:282-5. [PMID: 25130512 DOI: 10.1016/j.jcv.2014.07.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
350 Zeuzem S, Herrmann E. Dynamics of hepatitis C virus infection. Annals of Hepatology 2002;1:56-63. [DOI: 10.1016/s1665-2681(19)32176-3] [Cited by in Crossref: 15] [Article Influence: 0.8] [Reference Citation Analysis]
351 Crivellin C, De Martin E, Germani G, Gambato M, Senzolo M, Russo FP, Vitale A, Zanus G, Cillo U, Burra P. Risk factors in liver retransplantation: a single-center experience. Transplant Proc. 2011;43:1110-1113. [PMID: 21620065 DOI: 10.1016/j.transproceed.2011.01.141] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
352 Perelson AS, Herrmann E, Micol F, Zeuzem S. New kinetic models for the hepatitis C virus. Hepatology. 2005;42:749-754. [PMID: 16175615 DOI: 10.1002/hep.20882] [Cited by in Crossref: 107] [Cited by in F6Publishing: 81] [Article Influence: 6.7] [Reference Citation Analysis]
353 Van ND, Falk CS, Sandmann L, Vondran FW, Helfritz F, Wedemeyer H, Manns MP, Ciesek S, von Hahn T. Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. Gut 2016;65:1015-23. [PMID: 25800783 DOI: 10.1136/gutjnl-2014-308003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]